ESMO 2023 | What are the current unmet needs in metastatic pancreatic cancer?

Akihiro Ohba, MD, National Cancer Centre, Tokyo, Japan, comments on current challenges in the management of metastatic pancreatic cancer. Despite the Phase II/III JCOG1611-GENERATE (jRCTs031190009) trial showing the superiority of nab-paclitaxel and gemcitabine over modified FOLFIRINOX, survival rates are still below two years. Further research is therefore required to improve overall survival. This interview took place at the European Society for Medical Oncology (ESMO) 2023 Congress in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.